this is such a catch 22.....doctors have to have an objective way to monitor progression. As unreliable as it may be, it seems that an increase in MRI lesions is how most neuros measure progression. As well as the drug companies.....during clinical trials, the MRI lesion load is how they determine if a MS drug is effective.